VeriChip Corporation Outlines Current Applications and Potential Future Applications for its First-of-a-Kind Implantable RFID Implantable Microchip

Company`s Plans Continue to Evolve in Light of Government Demand for Personal
Health Record Access and the Need for Potential Diagnostic Applications
DELRAY BEACH, Fla.--(Business Wire)--
VeriChip Corporation ("VeriChip" or the "Company") (NASDAQ:CHIP), a provider of
radio frequency identification (RFID) systems for healthcare and patient-related
needs, today provided additional comments regarding its VeriMed Health Link
patient identification system following the recent passage of a bill by the
Pennsylvania House of Representatives banning forced microchip implantation in
humans, and also outlined its current and potential future applications for its
RFID implantable microchip. The VeriMed Health Link system was cleared by the
FDA in 2004 as a Class II medical device and is the first and only implantable
microchip cleared by the FDA for patient identification.

The Company`s VeriMed Health Link system is the connection between a patient and
their personal health record. It provides emergency room doctors and nurses with
immediate access to vital medical and emergency contact information, which will
help them to treat the patient rapidly, accurately and safely during an
emergency. Health Link utilizes a tiny microchip (similar in size to a grain of
rice), handheld scanner and a secure online database. The Health Link microchip
stores only a unique 16-digit identification number and is injected just under
the skin in the rear upper portion of the right arm. When a Health Link member
presents in an emergency department unconscious, unresponsive or confused,
emergency medical personnel use the Health Link scanner to retrieve the member`s
identification number to access his or her personal health record.

The Company has always focused on improving the health and welfare of high-risk
patients who chose its first-of-its-kind, FDA-cleared technology, the VeriMed
Health Link system. As the VeriMed Health Link system evolves from
identification to other applications including potential diagnosis and
treatment, with applications ranging from the glucose-sensing microchip to other
sensor applications and more, the Company envisions the full development of its
technology through various patents it holds. In light of the current
administration and its focus on personal health records, the Company anticipates
the continuing evolution of its intellectual property and technology.

One example of the Company`s current technology in action is its relationship
with Alzheimer`s Community Care, based in West Palm Beach, FL. More than 100
participating individuals, those suffering from Alzheimer`s disease and other
forms of dementia and their caregivers, have received the Health Link
implantable microchip to provide emergency department staff easy access to those
patients' identification and medical information.

In November 2008, VeriChip purchased all intellectual property related to
implantable human RFID and sensor technologies including, but not limited to,
Patent No. 7,125,382 entitled "Embedded Bio-Sensor System" from Digital Angel
Corporation. That patent is currently being utilized in connection with
VeriChip`s and its development partner`s, RECEPTORS LLC, efforts to jointly
develop a glucose-sensing device. VeriChip announced in December 2008 that the
Phase I proof-of-concept program successfully prepared prototype examples for
both the glucose-selective binding environment and the glucose-competitive
signaling component. These critical components were used to demonstrate the
bench top format application of the glucose-sensing system to the detection of
glucose levels. This demonstration is the proof-of-concept foundation of the
glucose-sensing system.

In May 2009, VeriChip, in conjunction with its development partner, announced
plans to develop surveillance and point-of-care sensor systems that will
efficiently detect and identify the presence of a particular biological threat
such as influenza virus, Methicillin-resistant Staphylococcus aureus (MRSA) or
other illnesses. The companies published a white paper outlining the development
of "An Integrated Sensor System for the Detection of Bio-Threats from Pandemics
to Emerging Diseases to Bio-Terrorism," which is available at
www.verichipcorp.com.

Silverman commented, "In November, I made a substantial investment in this
Company based on my belief in the technology, its current applications and its
potential in the future. As we look to the future, we place significant value on
our intellectual property, including our implantable microchip, and the
potential of a glucose-sensing device and related sensor applications, to
address healthcare, identification and security needs around the globe."

VeriChip expects to hold a conference call at the end of July to discuss recent
corporate events and the future direction of the Company. Additional details
will be provided in a press release at a later date.

About VeriChip

VeriChip Corporation, headquartered in Delray Beach, Florida, has developed the
VeriMed Health Link System for rapidly and accurately identifying people who
arrive in an emergency room and are unable to communicate. This system uses the
first human-implantable passive RFID microchip, cleared for medical use in
October 2004 by the United States Food and Drug Administration. To complement
its healthcare division, VeriChip Corporation established VeriGreen Energy
Corporation in March 2009 to focus and invest in the clean and alternative
energy sector.

For more information on VeriChip, please call 1-800-970-2447, or e-mail
info@verichipcorp.com. Additional information can be found online at
www.verichipcorp.com.

Statements about VeriChip`s future expectations, including future revenues and
earnings from the sale of its VeriMed Health Link patient identification system
and potential future applications including a glucose-sensing RFID implantable
microchip and other applications, and all other statements in this press release
other than historical facts are "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934, and as that term is defined in the Private Litigation
Reform Act of 1995. Such forward-looking statements involve risks and
uncertainties and are subject to change at any time, and VeriChip`s actual
results could differ materially from expected results. Additional information
about these and other factors that could affect the Company`s business is set
forth in the Company`s various filings with the Securities and Exchange
Commission, including those set forth in the Company`s 10-K filed on February
12, 2009, under the caption "Risk Factors." The Company undertakes no obligation
to update or release any revisions to these forward-looking statements to
reflect events or circumstances after the date of this statement or to reflect
the occurrence of unanticipated events, except as required by law.

VeriChip Corporation, Delray Beach
Allison Tomek, 561-805-8000
atomek@verichipcorp.com

Copyright Business Wire 2009